Ciforadenant Has Promising Anti-tumor Activity in mCRPC, Early Data Show

Ciforadenant Has Promising Anti-tumor Activity in mCRPC, Early Data Show
Treatment with Corvus Pharmaceuticals' ciforadenant (CPI-444), alone or in combination with Tecentriq (atezolizumab), is well tolerated and showed promising anti-tumor activity in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients, early data from a Phase 1b/2 clinical trial suggest. Lawrence Fong, MD, leader of the cancer immunotherapy program at the  Helen Diller Family Comprehensive Cancer Center at the University of California San Francisco, presented the findings at the American Society of Clinical Oncology (ASCO) 2020 Genitourinary Cancers Symposium. The poster presentation was titled, “Adenosine Receptor Blockade with Ciforadenant ± Atezolizumab in Advanced Metastatic Castration Resistant Prostate Cancer (mCRPC).” CD73 is a cell surface protein that is often elevated in metastatic prostate cancer patients and helps the tumor grow by dampening anti-tumor immune responses. It does so by increasing the levels of
Subscribe or to access all post and page content.